Martine George, MD
Principal & Senior Executive Consultant, Life Sciences
Global Development Associates, Inc.
Martine George, MD is a Medical Oncologist and Pharmaceutical Executive with over 25 years of experience in leading pharmaceutical and biotechnology organizations, with worldwide expertise in drug development including clinical research, regulatory affairs and medical affairs.
Currently, she is the Principal and Senior Executive Consultant, Life Sciences, for Global Development Associates, Inc., a consulting company specialized in drug development, and a Board Member of Erytech, Inc. and GamaMabs Pharma.
Most recently, she held the position of Vice President of Global Medical Affairs at Pfizer Oncology where she drove the global medical strategy and reimbursement activities for oncology drugs and NMEs. She was responsible for managing the worldwide medical affairs group, global medical communication, and the health economics-outcomes research groups.
Her previous experience includes the positions of Senior Vice President of Drug Development and Chief Medical Officer at GPC Biotech, Inc. and Senior Vice President and Head of Oncology for Johnson & Johnson, where she developed and implemented overall drug development strategies for the oncology therapeutic area across all J&J pharmaceutical companies.
Additionally, she led the medical affairs group at Rhone-Poulenc Rorer/Sanofi-Aventis, the worldwide clinical research and regulatory affairs at Gencell, and the Oncology clinical research and development at Sandoz Pharmaceuticals Corporation/Novartis. Prior to joining industry she held an academic and medical position at Institut Gustave Roussy, Villejuif, France for several years.
She received her M.Sc in Pharmacology from Montreal University, her M.D. from Pierre et Marie Curie University in Paris, and is board certified in Medical Oncology.
She was on the Leadership Council of the Cancer Institute of New Jersey, a board member of the Breast Cancer Foundation, and is a member of the American Society of Clinical Oncology.